Skip to main content

This site is intended for US residents.

OJEMDA (tovorafenib) logo: 100 mg tablets 25 mg/mL for oral suspension

Joseph, lives with pLGG

Educational resources

Discover more about OJEMDA

Whether you are just exploring your treatment options or your child has been prescribed OJEMDA, the resources below can help you wherever your family is in their pediatric low-grade glioma (pLGG) journey.

Review these materials so you can keep this useful information.

I am considering talking to my child’s doctor about OJEMDA

Doctor Discussion Guide

Considering discussing OJEMDA with your child's care team? This resource provides a list of questions to begin an open dialogue about OJEMDA and whether it might be right for your child.

Download

A Guide for Considering OJEMDA

Interested in learning more about OJEMDA treatment? Explore clinical trial results, possible side effects, and available patient support tailored to your family's needs.

Download

My child has been prescribed OJEMDA

What to Know When Starting OJEMDA

Just starting treatment with OJEMDA? Learn more about how to take OJEMDA, treatment routine tips, and potential side effects and how to manage them.

Download

Step-by-Step Guide for Preparing a Liquid Dose of OJEMDA

Need to learn how to prepare and give a liquid dose to your child? Master the step-by-step process for preparing your child's liquid medicine with this guide.

Download

Watch: The Instructional Video for preparing a liquid dose of OJEMDA

The video and step-by-step guide for preparing a liquid dose of OJEMDA allow you to learn in the style you choose.

Watch Video

EveryDay Support From Day One™ Brochure

Want to learn more about available support for patients taking OJEMDA? This brochure has all you need to know about EveryDay Support From Day One.

Download

Recursos en español

Guía para considerar OJEMDA

¿Le interesa saber más sobre el tratamiento con OJEMDA? Explore los resultados de los ensayos clínicos, los posibles efectos secundarios y el apoyo disponible para los pacientes, adaptado a las necesidades de su familia.

Descargar

Qué hay que saber al empezar el tratamiento con OJEMDA

¿Acaba de empezar el tratamiento con OJEMDA? Obtenga más información sobre cómo tomar OJEMDA, consejos sobre la rutina del tratamiento, y posibles efectos secundarios y cómo controlarlos.

Descargar

Guía paso a paso para preparar una dosis líquida de OJEMDA

¿Necesita aprender a preparar y administrar una dosis líquida a su hijo? Domine el proceso paso a paso para preparar el medicamento líquido de su hijo con esta guía.

Descargar
See frequently asked questions

Sign up

IMPORTANT SAFETY
INFORMATION

Before taking or giving OJEMDA, tell your healthcare provider about all of your or your child’s medical conditions, including if you:

  • have bleeding, skin, or liver problems
  • are pregnant or plan to become pregnant. OJEMDA can harm your unborn baby.

Females who are able to become pregnant:

  • You should use effective non-hormonal birth control (contraception) during treatment with OJEMDA and for 28 days after your last dose of OJEMDA.

Males with female partners who are able to become pregnant should use effective non-hormonal birth control (contraception) during treatment with OJEMDA and for 2 weeks after your last dose of OJEMDA.

  • are breastfeeding or plan to breastfeed. Do not breastfeed during treatment and for 2 weeks after your last dose of OJEMDA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What should I avoid while taking OJEMDA?

Limit the amount of time you spend in sunlight. OJEMDA can make your skin sensitive to the sun (photosensitivity). Use sun protection measures, such as sunscreen, sunglasses and wear protective clothes that cover your skin during your treatment with OJEMDA.

What are the possible side effects of OJEMDA?

OJEMDA may cause serious side effects, including:

  • bleeding problems (hemorrhage) are common and can also be serious. Tell your healthcare provider if you develop any signs or symptoms of bleeding, including:
    • headache, dizziness or feeling weak
    • coughing up blood or blood clots
    • vomiting blood or your vomit looks like "coffee grounds"
    • red or black stools that look like tar
  • skin reactions, including sensitivity to sunlight (photosensitivity). OJEMDA can cause skin reactions that can become severe. Tell your healthcare provider if you get new or worsening skin reactions, including:
    • rash
    • bumps or tiny papules
    • acne
    • peeling, redness, or irritation
    • blisters
  • liver problems. Your healthcare provider will do blood tests to check your liver function before and during treatment with OJEMDA. Tell your healthcare provider right away if you develop any of the following symptoms:
    • yellowing of your skin or your eyes
    • dark or brown (tea-colored) urine
    • nausea or vomiting
    • loss of appetite
    • tiredness
    • bruising
    • bleeding
    • pain in your upper right stomach area
  • slowed growth in children. Growth will be checked routinely during treatment with OJEMDA.

The most common side effects of OJEMDA include:

  • rash
  • hair color changes
  • tiredness
  • viral infection
  • vomiting
  • headache
  • fever
  • dry skin
  • constipation
  • nausea
  • acne
  • upper respiratory tract infection

OJEMDA may cause fertility problems in males and females, which may affect your ability to have children.

INDICATION

What is OJEMDA™ (tovorafenib)?

OJEMDA is a prescription medicine used to treat certain types of brain tumors (cancers) called gliomas in patients 6 months and older:

  • that is a pediatric low-grade glioma (LGG), and
  • that has come back after previous treatment or has not responded to previous treatment and
  • that has a certain type of abnormal “BRAF” gene.

These are not all the possible side effects of OJEMDA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Patient Information, including Instructions for Use, for more information.